Whitehawk Therapeutics (NASDAQ:WHWK) Stock Price Down 15.3% – Here’s Why

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) shares traded down 15.3% during mid-day trading on Friday . The company traded as low as $2.08 and last traded at $2.21. 2,719,309 shares traded hands during trading, a decline of 44% from the average session volume of 4,825,615 shares. The stock had previously closed at $2.61.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Whitehawk Therapeutics in a research note on Wednesday, October 8th. Zacks Research upgraded shares of Whitehawk Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 7th. Finally, Wall Street Zen lowered shares of Whitehawk Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, August 9th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Reduce”.

Whitehawk Therapeutics Trading Down 15.3%

The company has a 50 day simple moving average of $1.89. The company has a market cap of $104.15 million, a price-to-earnings ratio of -36.83 and a beta of 0.58.

Whitehawk Therapeutics (NASDAQ:WHWK) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.49 by ($1.25). Whitehawk Therapeutics had a negative return on equity of 75.99% and a net margin of 99.42%.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway.